Lipid Raft targeting of the TC10 amino terminal domain is responsible for disruption of adipocyte cortical actin.
Overexpression of the Rho family member TC10alpha, disrupts adipocyte cortical actin structure and inhibits insulin-stimulated GLUT4 translocation when targeted to lipid raft microdomains. This appears to be independent of effecter domain function because overexpression of the wild-type (TC10/WT), constitutively GTP-bound (TC10/Q75L), and constitutively GDP bound (TC10/T31N) all inhibit adipocyte cortical actin structure and GLUT4 translocation. To examine the structural determinants responsible for these effects, we generated a series of chimera proteins between TC10 with that of H-Ras and K-Ras. Chimera containing the 79 (TC10-79/H-Ras), 41 (TC10-41/H-Ras), or 16 (TC10-16/H-Ras) amino acids of the TC10 amino terminal extension fused to H-Ras disrupted cortical actin and inhibited insulin-stimulated GLUT4 translocation. In contrast, the same amino terminal TC10 extensions fused to K-Ras had no significant effect on either GLUT4 translocation or cortical actin structure. Similarly, expression of TC10beta was without effect, whereas fusion of the amino terminal 8 amino acid of TC10alpha onto TC10beta resulted in an inhibition of insulin-stimulated GLUT4 translocation. Within the amino terminal extension point mutation analysis demonstrated that both a GAG and GPG sequences when lipid raft targeted was essential for these effects. Furthermore, expression of the amino terminal TC10 deletions DeltaNT-TC10/WT or DeltaNT-TC10/T31N had no detectable effect on cortical actin organization and did not perturb insulin-stimulated GLUT4 translocation. Surprisingly, however, expression of DeltaNT-TC10/Q75L remained fully capable of inhibiting insulin-stimulated GLUT4 translocation without affecting cortical actin. These data demonstrate that inhibitory effect of TC10 overexpression on adipocyte cortical actin organization is due to the specific lipid raft targeting of the unusual TC10 amino terminal extension.
Chunqiu Hou
June
J
The Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, New York 11794-8651, USA.
Pessin
Jeffrey E
JE
D041721:3T3-L1 Cells; D000199:Actins / Q000502:physiology*; D017667:Adipocytes; D000818:Animals; D002478:Cells, Cultured; D004268:DNA-Binding Proteins; D011905:Genes, ras / Q000235:genetics / Q000502:physiology; D007328:Insulin / Q000494:pharmacology*; D021962:Membrane Microdomains / Q000378:metabolism* / Q000502:physiology; D051379:Mice; D008845:Microinjections; D009154:Mutation; D017434:Protein Structure, Tertiary / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D014157:Transcription Factors / Q000187:drug effects / Q000378:metabolism*; D020741:rho GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism* / Q000502:physiology
D000199:Actins; D004268:DNA-Binding Proteins; D007328:Insulin; D011993:Recombinant Fusion Proteins; C480633:SLC2A4RG protein, human; D014157:Transcription Factors; C503256:RHOQ protein, human; C503260:Rhoq protein, mouse; D020741:rho GTP-Binding Proteins